NR ATJL
AU Abdel-Haq,H.; Coker,S.S.; Cardone,F.; Pocchiari,M.
TI Removal of mouse - adapted human variant CJD infectious prions from red cell concentrates using Pall leukotrapTM affinity prion reduction filter.
QU International Conference - Prion 2005: Between fundamentals and society's needs - 19.10.-21.10.2005, Congress Center Düsseldorf - Poster Session: Decontamination DEC-18
PT Konferenz-Poster
AB
INTRODUCTION: The identification of variant CJD (vCJD) infection in two recipients of blood donations from people who subsequently developed vCJD and the increase in the number of countries with vCJD cases underlines the risk of transmission of the agent through blood transfusions from infected individuals with no clinical symptoms of the disease and requires the introduction of safeguard measures to preserve the safety of blood and blood products. OBJECTIVE: In the present study we evaluated the use of the new Pall's Leukotrap Affinity prion reduction filter for the removal of vCJD agent from blood.
MATERIALS AND METHODS: Seven units of non-leukocyte reduced red cell concentrates (RCC) in SAGM additive solution were prepared from Citrate Phosphate dextrose (CPD) anticoagaulated whole blood. About 3mL of 10% mouse vCJD brain homogenate (mvCJDBH) or normal brain in phosphate buffered saline was added to 297mL each of five units of non-leucocyte reduced human RCC. The RCC were filtered at room temperature with Pall Leukotrap Affinity prion reduction filter (PLAPRF) at a filtration height of 76.2cm. The remaining two units of RCC were initially filtered with Pall BPF4 high efficiency leucocyte reduction filter before being spiked with mvCJDBH and then filtered with PLAPRF. Removal of mouse vCJD from RCC was quantified using end point dilution method by Western blot detection of PrPtse. RESULTS: Western blot consistently shows that the PLAPRF removed at least 2.0 - 2.5 logs of mouse vCJD spike from leucodepleted and non leucodepleted RCC respectively. CONCLUSION: These results show that Pall Leukpotrap Affinity prion reduction filter is effective in removing mvCJD from RCC. The use of this filter will help to reduce the risk of transmission of vCJD through blood transfusion. Additional studies using bioassay to confirm the log reduction and an endogenous infectivity study to demonstrate protection from transmission of mvCJD are needed.
IN Experimentell stellten die Autoren fest, dass der "Pall Leukotrap Affinity prion reduction filter" (PLAPRF) die nvCJK-Infektiosität von Blut um mindestens 2-2,5 Größenordnungen zu reduzieren vermag.
AD Hanin Abdel-Haq, Franco Cardone, Maurizio Pocchiari, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, Rome, Italy; Samuel S. Coker, Pall Medical, Pall Corporation, Port Washington, New York, USA
SP englisch
PO Deutschland